{
    "clinical_study": {
        "@rank": "1349", 
        "arm_group": [
            {
                "arm_group_label": "Anacetrapib 100 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Anacetrapib 25 mg", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate the effects of 2 different dose levels of anacetrapib on\n      low-density lipoprotein-cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C)\n      in participants with hypercholesterolemia  when added to an existing statin-modifying\n      therapy."
        }, 
        "brief_title": "A Study of the Safety and Efficacy of Anacetrapib (MK-0859) When Added to Ongoing Statin Therapy (MK-0859-021)", 
        "completion_date": {
            "#text": "February 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypercholesterolemia", 
        "condition_browse": {
            "mesh_term": "Hypercholesterolemia"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  If female, cannot be of reproductive potential\n\n          -  Have been treated with an optimal dose of statin for at least 6 weeks\n\n          -  Coronary heart disease (CHD) or other atherosclerotic vascular disease with multiple\n             risk factors (including diabetes, metabolic syndrome) and/or high LDL-C/low HDL-C, or\n             needing to meet a specific LDL-C/HDL-C goal\n\n        Exclusion Criteria:\n\n          -  Previously participated in a study with a cholesteryl ester transfer protein (CETP)\n             inhibitor\n\n          -  Homozygous familial hypercholesterolemia\n\n          -  Severe chronic heart failure\n\n          -  Uncontrolled cardiac arrhythmias, myocardial infarction (MI), percutaneous coronary\n             intervention (PCI), coronary artery by-pass graft (CABG), unstable angina, or stroke\n             within 3 months\n\n          -  Uncontrolled hypertension\n\n          -  Uncontrolled endocrine or metabolic disease known to influence serum lipids or\n             lipoproteins\n\n          -  Active or chronic hepatobiliary, hepatic, or gall bladder disease\n\n          -  History of mental instability, drug/alcohol abuse within the past five years or major\n             psychiatric illness inadequately controlled and unstable\n\n          -  History of ileal bypass, gastric bypass, or other significant condition associated\n             with malabsorption\n\n          -  Human immunodeficiency virus (HIV) positive\n\n          -  History of malignancy \u22645 years\n\n          -  Donated blood products or has had phlebotomy of >300 mL within 8 weeks or intends to\n             donate 250 mL of blood products or receive blood products within the projected\n             duration of the study\n\n          -  Currently taking medications that are potent inhibitors or inducers of cytochrome\n             P450 3A4 (CYP3A) (including but not limited to cyclosporine, systemic itraconazole or\n             ketoconazole, erythromycin, clarithromycin, or telithromycin, nefazodone, protease\n             inhibitors, carbamazepine, phenobarbital, phenytoin, rifabutin, rifampin, St John's\n             wort) or has discontinued treatment <3 weeks prior\n\n          -  Consumes more than 2 alcoholic drinks per day\n\n          -  Currently participating or has participated in a study with an investigational\n             compound or device within 3 months\n\n          -  Receiving treatment with systemic corticosteroids or taking systemic anabolic agents"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "450", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "October 26, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01717300", 
            "org_study_id": "0859-021", 
            "secondary_id": "2012-003110-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Anacetrapib 100 mg", 
                "description": "100 mg tablet, oral, once daily for 24 weeks", 
                "intervention_name": "Anacetrapib 100 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-0859"
            }, 
            {
                "arm_group_label": [
                    "Anacetrapib 25 mg", 
                    "Placebo"
                ], 
                "description": "Placebo tablet, orally, once daily for 24 weeks", 
                "intervention_name": "Placebo for anacetrapib 100 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Anacetrapib 25 mg", 
                "description": "25 mg tablet, oral, once daily for 24 weeks", 
                "intervention_name": "Anacetrapib 25 mg", 
                "intervention_type": "Drug", 
                "other_name": "MK-0859"
            }, 
            {
                "arm_group_label": [
                    "Anacetrapib 100 mg", 
                    "Placebo"
                ], 
                "description": "Placebo tablet, orally, once daily for 24 weeks", 
                "intervention_name": "Placebo for anacetrapib 25 mg", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Oxazolidinones"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "February 13, 2014", 
        "number_of_arms": "3", 
        "official_title": "A 24-Week, Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Anacetrapib When Added to Ongoing Statin Therapy With or Without Other Lipid Modifying Medication(s) in Patients With Hypercholesterolemia or Low HDL-C", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percent Change from Baseline in LDL-C (beta-quantification [BQ] method)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in HDL-C", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Number of Participants with Alanine Transaminase (ALT) or Aspartate Aminotransferase (AST) Consecutive Elevations \u22653xULN (Upper Limit of Normal)", 
                "safety_issue": "Yes", 
                "time_frame": "24 Weeks"
            }, 
            {
                "measure": "Number of Participants with Creatine Phosphokinase Elevations \u226510xULN with or without Muscle Symptoms", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of Participants with Sodium, Chloride, or Bicarbonate Elevations >ULN or Potassium Levels <LLN (Lower Limit of Normal)", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of Participants with Pre-specified Adjudicated Cardiovascular Serious Adverse Events or Death from Any Cause", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }, 
            {
                "measure": "Number of Participants with Significant Increase in Blood Pressure", 
                "safety_issue": "Yes", 
                "time_frame": "24 weeks"
            }
        ], 
        "removed_countries": {
            "country": [
                "United States", 
                "Bulgaria", 
                "Canada", 
                "Germany", 
                "Hungary", 
                "Israel", 
                "Netherlands", 
                "Poland", 
                "Puerto Rico", 
                "Romania", 
                "Slovakia", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01717300"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percent change from Baseline in non-HDL-C", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Apolipoprotein B (Apo-B)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Apolipoprotein A-I (Apo-A-I)", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in Lipoprotein(a) (lp[a])", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }, 
            {
                "measure": "Percent Change from Baseline in HDL-C Among Participants with Low HDL-C at LDL-C goal", 
                "safety_issue": "No", 
                "time_frame": "Baseline and Week 24"
            }
        ], 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}